Symptoms include weight loss, elevated heart rate, anxiety and diarrhoea
Oral: Oral BPC-157 typically requires 37 days of consistent dosing before users notice benefits
Research has identified these alarming vision-related risks associated with GLP-1 medications: Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication
Payers typically require: Documentation that you tried the preferred medication first (step therapy) BMI of 30+ or 27+ with a weight-related comorbidity Proof of lifestyle modification (diet and exercise logs, often for 3-6 months) Compounded alternatives: Compounded semaglutide and compounded tirzepatide are available from U.S
Semaglutide & Tirzepatide Weekly Injection GLP-1 receptor agonists like compounded GLP-1 medications have revolutionized medical weight loss
We estimate that the final update to the conversion factor will increase total OPPS payments by 2.6 percent in CY 2026
